secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sage Therapeutics, Inc. (—)
CIK:        0001597553
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001193125-25-045671
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sage Therapeutics CMO Laura Gault resigns, effective March 21; CSO Quirk to lead clinical programs on interim basis
--------------------------------------------------------------------------------

- Laura Gault, M.D., Ph.D. resigns as CMO effective March 21, 2025, to pursue a new opportunity.
- Resignation is not due to any disagreement with Sage Therapeutics.
- Mike Quirk, Ph.D., current CSO, will assume interim oversight of clinical development programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1597553/000119312525045671/0001193125-25-045671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1597553/000119312525045671/d939383d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-045671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer